Relyto 100mg/10ml Infusion

Uses of Relyto 100mg/10ml Infusion

• Non-Hodgkin’s disease
• Rheumatoid arthritis
• Chronic lymphocytic Leukemia
• Granulomatosis
• Pemphigus Vulgaris

How does Relyto 100mg/10ml Infusion work?

Rituximab is a monoclonal antibody, that works by targeting the unwanted activity of blood cells. This helps in managing cancer.

Side Effects of Relyto 100mg/10ml Infusion

• Headache
• Weakness
• Infection
• Chills
• Decreased white blood cell count (neutrophils)
• Fever
• Infusion site reaction
• Lymphopenia
• Abdominal pain
• Back pain

Quick Suggestions:

• This medicine is usually administered by a qualified healthcare professional in the hospital or clinical setting.
• Inform the doctor if you have a known history of allergy to this medicine.
• Report to the doctor all your current medicines including any herbs and supplements as well as your medical conditions before receiving this medicine.
• Report any unusual and significant side effects to the doctor immediately.

Indication

Non-Hodgkin's Lymphoma:

• Rituximab is used in the treatment of non-Hodgkin's lymphoma, a type of cancer that affects certain cells (lymphocytes) of the lymphatic system. It is particularly effective against B-cell non-Hodgkin's lymphoma.

Chronic Lymphocytic Leukemia (CLL):

• Rituximab is utilized in the treatment of chronic lymphocytic leukemia, which is a type of blood cancer involving abnormal lymphocytes.

Rheumatoid Arthritis:

• Rituximab is employed in the treatment of rheumatoid arthritis, a chronic autoimmune condition that affects the joints.

Granulomatosis with Polyangiitis and Microscopic Polyangiitis:

• Rituximab is used in combination with other medicines for the treatment of granulomatosis with polyangiitis (formerly known as Wegener's granulomatosis) and microscopic polyangiitis. These are chronic conditions affecting blood vessels, potentially leading to inflammation and damage to various organs.

Pharmacology

Monoclonal Antibody:

• Relyto 100mg/10ml Infusion is a monoclonal antibody, specifically rituximab.
• Monoclonal antibodies are laboratory-made molecules designed to mimic the immune system's ability to fight off harmful pathogens, including cancer cells and autoimmune triggers.

Immune Cell Destruction:

• Rituximab targets and destroys B-cells, a type of immune cell.
• This action is particularly important in the context of cancer treatment, where uncontrolled B-cell growth can contribute to cancer formation.

Reduction of Inflammatory Chemicals:

• Relyto 100mg/10ml Infusion reduces the production of certain chemicals in the body, including:
  • Rheumatoid factor: Associated with autoimmune conditions like rheumatoid arthritis.
  • T-cells: Involved in immune responses.
  • Cytokines: Signaling molecules that contribute to inflammation.

Cancer Treatment:

• Used in the treatment of blood cancers such as leukemia and lymphomas.
• By targeting B-cells, it helps control the progression of cancer.

Autoimmune Diseases:

• Used in autoimmune conditions like rheumatoid arthritis, granulomatosis with polyangiitis, microscopic polyangiitis, and pemphigus vulgaris.
• Reducing inflammatory responses helps alleviate symptoms like pain, swelling, and tissue damage associated with these conditions.

Dosage & Administration of Relyto 100mg/10ml Infusion

Non-Hodgkin's Lymphoma:

• Refractory or relapsed follicular lymphoma: Single-agent infusion of 375 mg/m2 once weekly for 4 doses.
• When used with CVP or CHOP, 375 mg/m2 on day 1 of the chemotherapy cycle for up to 8 cycles.
• For patients not progressing after 6-8 cycles of CVP, 375 mg/m2 may be given once weekly for 4 doses, repeat every 6 months, for up to 16 doses.
• Maintenance: 375 mg/m2 given once every 3 months (responded to induction chemotherapy) or once every 2 months initiated 2 months after the last dose of induction chemotherapy (previously untreated) for a maximum period of 2 years.

Chronic Lymphocytic Leukemia (CLL):

• 375 mg/m2 on the day before chemotherapy in cycle 1, followed by 500 mg/m2 on day 1 (every 28 days) of cycles 2-6.

Rheumatoid Arthritis:

• Two 1 g IV infusion doses, separated by 2 weeks, in combination with methotrexate.
• Corticosteroids may be given before each infusion to minimize the risk and severity of infusion reactions.

Administration:

• Relyto 100mg/10ml Infusion will be given intravenously by a doctor or a nurse.
• Initial infusion rate: 50 mg/hr, may increase by 50 mg/hr every 30 minutes. If tolerated, subsequent infusions can start at 100 mg/hr, increased by 100 mg/hr every 30 minutes. Max rate: 400 mg/hr.

Duration of Therapy:

• The correct dose and duration of therapy will be determined by your doctor based on factors such as age, body weight, and disease condition.

Overdose:

• Your doctor or nurse administers Relyto 100mg/10ml Infusion, minimizing the likelihood of accidental overdose.
• If you experience symptoms of overdose after receiving the injection, seek immediate medical assistance.

Missed Dose:

• Your doctor or nurse will monitor and determine the timing of Relyto 100mg/10ml Infusion administration.
• It is unlikely that a dose will be missed. If you suspect a missed dose or have concerns, inform your doctor or nurse promptly.

Interaction

Drug-Drug Interactions:

• Vaccines: Relyto 100mg/10ml Infusion may interact with vaccines, affecting their efficacy.
• Antineoplastic Drugs (Cisplatin): Interaction with cisplatin may increase the risk of renal toxicity.

Drug-Food Interactions:

• No interactions between Relyto 100mg/10ml Infusion and food have been reported.

Drug-Disease Interactions:

• Inform your doctor if you have pre-existing conditions such as kidney or liver disease, gastrointestinal disorders, or pulmonary disorders before receiving Relyto 100mg/10ml Infusion. This information is crucial for determining the suitability of the medication based on your health status.

Contraindications

If you are allergic to rituximab or any of the other ingredients of Relyto 100mg/10ml Infusion If you have any active infections If your immune system is weak If you have any heart disease

Pregnancy & Lactation

Pregnancy group C. Animal studies have shown adverse effects on the fetus (teratogenic or embryotoxic or others) and there are no controlled studies in women or no studies. in women and animals. The drug should be used only if there is a potential benefit to the fetus.

Precautions & Warnings

Allergy:

• Avoid Relyto 100mg/10ml Infusion if you are allergic to it or any of its components.

Medical History:

• Provide your complete medical history to your doctor, including current medications, to rule out potential side effects or interactions.

Liver/Kidney Disease:

• Inform your doctor if you have liver or kidney disease before administration.

Hepatitis B Virus Infection:

• Notify your doctor if you have a history of hepatitis B virus infection.

Cardiac Disorders:

• If you have cardiac disorders, consult your doctor before using Relyto 100mg/10ml Infusion.

Active Infections:

• Inform your doctor about any ongoing infections before starting the treatment.

Gastrointestinal Disorders:

• Patients with gastrointestinal disorders should exercise caution, as Relyto 100mg/10ml Infusion may cause bowel obstruction and perforation.

Bowel Obstruction and Perforation:

• Be aware of the risk of bowel obstruction and perforation associated with Relyto 100mg/10ml Infusion.

Reactivation of Hepatitis B Infection:

• Regular monitoring is essential, as the medication may lead to the reactivation of Hepatitis B infection.

Cardiac Arrhythmias and Angina:

• Patients may experience cardiac arrhythmias and angina; therefore, careful monitoring is necessary.

Tumour Lysis Syndrome:

• There is a risk of tumor lysis syndrome, where tumor cells release their contents into the bloodstream.

Pregnancy and Breastfeeding:

• Inform your doctor if you are pregnant, planning to become pregnant, or breastfeeding.

Storage Conditions

• Store in a refrigerator (2 °C – 8 °C). Keep the container in the outer carton to protect it from light.
• Keep it out of the reach of children.